FDA 483 - Jubilant Generics Limited - February 02, 2024

Jubilant Generics Limited in Roorkee, India, was cited for significant deficiencies in its quality control and manufacturing processes during an FDA inspection. Observations included inadequate investigations into cleaning verification failures, poor documentation practices, and insufficient validation studies for critical process parameters. These issues indicate a lack of robust quality oversight and control over drug product manufacturing.